Risks to safety of vitamin B6 injection

doi:10.19803/j.1672-8629.20230067

Abstract

Abstract: Objective To analyze the risks to safety posed by vitamin B₆ injection in China in order to provide reference for clinical rational drug use. Methods The individual cases of adverse drug reactions retrieved from China adverse drug reaction database (from January 1, 2004 to June 30, 2019) and WHO Vigilyze (from inception to January 31, 2023), and other databases (from inception to December 31, 2020) were analyzed. Results The risk posed by vitamin B₆ injection, general disorders, and related cutaneous and gastrointestinal system damage deserved more attention. Conclusion Drug marketing authorization holders should reinforce the safety monitoring of vitamin B₆ injection, update the drug labeling in a timely manner and promote the rational use of medicines.

Key words: vitamin B₆, drug adverse reaction, safety, risk, regulatory measures, instruction, drug marketing authorization holders

CLC Number:

YANG Le, XIA Dongsheng, WANG Tao. Risks to safety of vitamin B₆ injection[J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 791-794.

References

[1] Sean C Sweetman Martindale. The Complete Drug Reference[M]. 37th ed. Beijing: Chemical Industry Press, 2013.
[2] National Medical Security Bureau. List of national basic medical insurance, industrial injury insurance and maternity insurance drugs (2019 version) [EB/OL].(2019-08-20)[2023-01-10].http://www.nhsa.gov.cn/art/2019/8/20/art_37_1666.html.
[3] Chinese Pharmacopoeia Commission.Pharmacopoeia of the People’s Republic of China,Volume I I(中华人民共和国药典二部)[M]. Beijing: China Medical Science Press, 2020: 1478.
[4] National Medical Products Administration. Data Search[EB/OL].[2023-01-10]. https://www.nmpa.gov.cn/datasearch/home-index.html?79QlcAyHig6m=1679362834884#category=yp .
[5] SUN Q, JIANG YS.A case of peripheral nerve damage caused by high-dose vitamin B₆ intravenous injection[J]. Chinese Journal of Clinical Pharmacy(中国临床药学杂志), 2002, 11(2): 109.
[6] CHEN TX.Symptoms of excessive vitamin B₆[J]. Chinese Journal of Hospital Pharmacy(中国医院药学杂志), 1986, 6(9): 47.
[7] MEYER HE, WILLETT WC, FUNG TT et al. Association of high intakes of vitamins B₆ and B₁₂ from food and supplements with risk of hip fracture among postmenopausal women in the nurses' health study[J]. JAMA Netw Open, 2019, 2(5): e193591.
[8] CALDERON-OSPINA CA, NAVA-MESA MO, PAEZ-HURTADO AM.Update on safety profiles of vitamins B₁, B₆, and B₁₂: a narrative review[J]. Ther Clin Risk Manag, 2020, 16: 1275-1288.
[9] RAO DB, JORTNER BS, SILLS RC.Animal models of peripheral neuropathy due to environmental toxicants[J]. ILAR J, 2014, 54(3): 315-323.
[10] VROLIJK MF, OPPERHUIZEN A.The vitamin B₆ paradox: Supplementation with high concentrations of pyridoxine leads to decreased vitamin B₆ function[J]. Toxicol In Vitro, 2017, 44: 206-212.
[11] XU XH.A case of benign lethargy in children caused by vitamin B₆[J]. Henan Med Inf(河南医药信息), 2002, 10(4): 30.
[12] CHENG F, YANG HH.A case report of allergic dermatitis caused by vitamin B₆ injection[J]. Qinghai Medical Journal(青海医药杂志)2019, 49(1): 20.
[13] WANG XQ, PAN JJ.There are incompatibilities between 15 drugs and vitamin B₆ injection[J]. China Rural Medicine(中国乡村医药), 2015, 22(17): 83-84.
[14] ZHANG XN, ZHANG LM.Stability observation of esomeprazole sodium for injection in different solvents and compatibility with different drugs[J]. Shandong Pharmaceutical(山东医药), 2016, 56(7): 24-26.
[15] CAO FP.Study on the stability of the compatibility of cefotaxime sodium and vitamin B₆ injection[J]. Anhui Pharmaceutical(安徽医药), 2005, 9(3): 169-170.
[16] YU ZN.Contraindications and cause analysis of intravenous drug compatibility[J]. Channel Pharmaceutical(海峡药学), 2016, 28(6): 227-229.
[17] NMPA. Announcement of the National Medical Products Administration on the amendment of the manual for vitamin B₆ injection(No.97 of2021)[EB/OL].(2021-07-22)[2023-01-10]. https://www.nmpa.gov.cn/xxgk/ggtg/ypshmshxdgg/20210727155255110.html.

Risks to safety of vitamin B₆ injection

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

[1]	JIA Yinyin, ZHANG Caishu, ZHOU Ying, LIU Li, GENG Ying, WEI Ningyi, NIU Sijing, CHEN Hua, XU Hui. Evaluation methods for aerodynamic particle size distribution of fine particles in inhaled products [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 141-146.
[2]	MA Meiying, ZHAO Xiaopei, ZHANG Mengyao, HU Yilin. Drug traceability coding system in China [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 167-172.
[3]	ZHANG Jian, FANG Huihua. Applicability of evaluation standards for use of traditional Chinese medicine injections for promoting blood circulation and removing blood stasis [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 185-189.
[4]	GAO Yunjuan, ZHAO Xu, BAI Tiankai, BAI Zhaofang, WANG Jiabo, SONG Haibo, XIAO Xiaohe. Discovery and identification strategy for drug safety risks based on big data monitoring of adverse reactions [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 1-5.
[5]	BAI Zhaofang, ZHAN Xiaoyan, YAO Qing, CHEN Simin, ZHAO Xu, XIAO Xiaohe. Theoretical innovation and technological breakthroughs in the safety evaluation of traditional Chinese medicine: disease-syndrome-based toxicology [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 6-14.
[6]	GUO Longxin, GAO Yunjuan, WU Chengzhao, LONG Minjuan, ZHU Shengkai, SONG Haibo, ZHAO Xu, XIAO Xiaohe. Exploring new risk signals and susceptibility factors of traditional Chinese medicine-induced hepatotoxicity based on big data from adverse reaction monitoring [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 15-19.
[7]	FANG Zhie, LI Chengxian, BAI Zhaofang, ZHAO Xu, WANG Jiabo, XIAO Xiaohe. Investigation of objectivity in the relationship between aristolochic acid and hepatocellular carcinoma [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 20-24.
[8]	XIONG Weiyi, REN Jingtian. Considerations for revision of safety information in package inserts of anti-cancer drugs in post-market phase [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 94-97.
[9]	LIU Min, CHEN Yan, LIU Wendong, WANG Haixue. Updates and reflections on expedited reporting of safety information during drug clinical trials [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 98-101.
[10]	CHEN Huayan, JIANG Dongbo, GUO Chunlian, YANG Jiaqi, LI Yuxin, CAI Weiming. Safety of nirmatrelvir/ritonavir in the treatment of novel coronavirus infections [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 107-110.
[11]	LI Xiaozhu, WANG Qiang, PANG Yu, ZHANG Yijing. Management of individual adverse drug reaction reports [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 975-977.
[12]	SHEN Yanjie, WU Yiqing. Management of adverse events during clinical trials [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 982-986.
[13]	YUAN Sisi, WANG Guangyan, LI Yifan, LI Ruilian, DU Boran, FENG Xin. Safety-related risk factors in clinical management of narcotics and psychotropic substances via failure mode and effect analysis [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1027-1030.
[14]	ZHU Yuanchao, ZHANG Yatong, HU Xin. Principles and measures of medication risk management in the elderly [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1031-1034.
[15]	LIU Qian, HU Jing, LI Bo, YANG Xiaojing. Jinghuaweikang capsules combined with quadruple therapy in the treatment of Helicobacter pylori associated gastritis: a systematic evaluation and meta-analysis [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1039-1045.